A Versatile Platform for Inactivation and Destruction  by Whitby, Frank G. & Hill, Christopher P.
Structure
PreviewsA Versatile Platform
for Inactivation and Destruction
Frank G. Whitby1 and Christopher P. Hill1,*
1 Department of Biochemistry, 15 North Medical Drive East, Room 4100, University of Utah, Salt Lake City, UT 84103, USA
*Correspondence: chris@biochem.utah.edu
DOI 10.1016/j.str.2007.01.009
In this issue of Structure, Yokoyama and coworkers report a complex structure that reveals how
gankyrin binds to another subunit of the 26S proteasome and that has implications for its interactions
with phosphorylation and ubiquitylation targeting factors as well as tumor suppressor substrates
(Nakamura et al., 2007).Proteins that integrate information
through multiple interactions and co-
ordinate or participate in the workings
of molecular machines are of excep-
tional interest. Gankyrin, named for
gann (Japanese for cancer) and its
seven ankyrin repeat structure, is one
such protein (Dawson et al., 2006).
Gankyrin is an oncogene that is highly
expressed in hepatic cancers. It is
also conserved from yeasts to human
as the p28 subunit of a remarkable
molecular machine called the 26S
proteasome.
Ankyrin motifs are 33 residue seg-
ments that adopt a b-hairpin-helix-
loop-helix fold, and they typically oc-
cur in multiple copies that stack into
an extended, curved structure. These
repeats serve as binding platforms
for other proteins. All surfaces of the
ankyrin architecture can be used to
bind partner proteins (Sedgwick and
Smerdon, 1999).
The 26S proteasome comprises a
700 kDa, 28 subunit protease called
the 20S proteasome that is capped at
one or both ends by the 900 kDa 19S
activator (Pickart and Cohen, 2004).
Detailed structural information for the
19S activator is lacking, but it probably
includes six ATPase subunits that,
like many other members of the AAA
ATPase family, may form a ring struc-
ture that unfolds substrate proteins
and translocates them into the 20S
proteasome’s central proteolytic
chamber. Other 19S subunits include
enzymes that perform processing or
editing roles, and structural proteins
that serve as docking platforms for
binding partners. Most substrates are
targeted to the 26S proteasomeby ubiquitylation, although ubiquitin-
independent pathways also occur.
Gankyrin is a subunit of the 19S ac-
tivator by virtue of its interaction with
the C-terminal domain of the 19S S6b
ATPase (S6-C). A paper by Nakamura
et al. (2007) in this issue advances
our understanding of activator archi-
tecture by reporting the crystal struc-
ture of a gankyrin/S6-C complex. The
new structure reveals that the helical
S6-C nestles against the concave face
of gankyrin to contact the first six an-
kyrin repeats and bury more than
2000 A˚2 of mostly polar surface area
(Figure 1, top left). The relevance of
this crystallographic interface is sup-
ported by mutagenesis and coexpres-
sion/purification studies: the S6-C is
insoluble when expressed alone in
E. coli, but is stable and soluble when
coexpressed with gankyrin. As noted
by Nakamura et al. (2007), docking of
full-length AAA ATPase structures
onto the S6-C indicates that the struc-
ture is compatible with binding to
the full-length S6b protein. We have
extended this view with a specula-
tive composite model for docking of
gankyrin onto the 26S proteasome
(Figure 1, right). As illustrated, the ga-
nykrin/S6-C crystal structure is com-
patible with binding to a proposed
19S activator model with gankyrin
binding on the outer surface of the
AAA ATPase ring.
Gankyrin’s role in cancer depends
in part upon its interaction with the ret-
inoblastoma (Rb) tumor suppressor,
leading to that protein’s degradation.
The interaction site has been mapped
to the 178LxCxE182 motif in the sixth
ankyrin repeat (Higashitsuji et al.,Structure 15, February 2007 ª2000). Curiously, although the same
peptide motif from the human papil-
loma virus E7 protein has been visual-
ized structurally in an extended con-
formation bound to the Rb pocket
domain (Lee et al., 1998), the interac-
tion with gankyrin is likely to be quite
different, because the gankyrin LxCxE
peptide is highly structured and largely
buried. Nevertheless, the coexpres-
sion/purification assays of Nakamura
et al. (2007) indicate that E182, which
is located at the edge of the S6-C inter-
face, is important for binding with Rb
and formation of a Rb/gankyrin/S6-C
ternary complex. Thus, one possible
role for gankyrin is to localize Rb in
the vicinity of the ATPases for process-
ing and degradation.
Gankyrin also promotes the phos-
phorylation of Rb (Li and Tsai, 2002).
This is important because hypophos-
phorylated Rb binds and inhibits the
E2F transcription factor, whereas hy-
perphosphorylated Rb releases E2F
to promote transcription of genes for
DNA synthesis and cell cycle progres-
sion. Rb is phosphorylated by cyclin-
dependent kinases, including the
close relatives CDK4 and CDK6, which
can be inactivated by binding of inhib-
itors such as p16INK4A. The crystal
structure of a CDK6-p16INK4A complex
(Russo et al., 1998) revealed that the
inhibitor is also an ankyrin repeat pro-
tein and that it binds to the kinase
N-terminal domain to induce a confor-
mational distortion at the enzyme
active site. Gankyrin binds an active
form of CDK4 through its N-terminal
ankyrin repeats and relieves the inhi-
bition by displacing p16INK4A (Li and
Tsai, 2002). It is therefore attractive to2007 Elsevier Ltd All rights reserved 137
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Proteasome and CDK4
Top left: Crystal structure of the complex between gankyrin (green) and S6-C (yellow) (Nakamura
et al., 2007). The Glu182 residue (red) implicated in binding Rb is indicated. Right: Speculative
composite model showing a rough EM image outline (thick line) of the 26S proteasome superim-
posed with a 20S crystal structure and the HslU AAA ATPase hexamer (Pickart and Cohen, 2004).
Gankyrin was modeled in this complex by superposition of the S6-C with the corresponding
region of HslU. The arrow connects the Glu182 Rb binding site with the likely path through the axial
ATPase and 20S pores. Bottom left: Gankyrin-CDK4 complex model based upon the CDK6-
p16INK4A complex structure (Padmanabhan et al., 2004). This model is incompatible with simulta-
neous binding of the S6-C.speculate that gankyrin binding will
be the same as p16INK4A, but will not
induce the conformational change,
and will thereby promote phosphoryla-
tion of Rb by active CDK4. The plausi-
bility of this model was demonstrated
by Padmanabhan et al. (2004), who
docked the unliganded gankyrin struc-
ture onto the CDK6INK4A complex.
Gankyrin also functions in the deg-
radation of another prominent tumor
supressor, p53. By binding the ubqui-
tin ligase MDM2, gankyrin promotes138 Structure 15, February 2007 ª2007 Ep53 ubiquitylation and subsequent
proteasomal degradation (Higashitsuji
et al., 2005). Notably, MDM2 has also
been implicated in the proteasomal
degradation of Rb (Higashitsuji et al.,
2005). These observations support a
model in which gankyrin serves as
an assembly platform for enzymes
(kinases and ubiquitin ligases) that
modify substrates (Rb and p53) and
also directly facilitates proteasome
targeting by binding to the S6b
ATPase.lsevier Ltd All rights reservedIn the CDK4 docking model outlined
above, the kinase overlaps substan-
tially with the site of bound S6-C
on gankyrin (Figure 1). Consequently,
it seems most likely that gankyrin
functions in at least two separate com-
plexes, although this inference is ten-
tative in the absence of further data.
Other important issues include the
potential relationship between distinct
gankyrin complexes, the functional re-
lationship between gankyrin and other
transiently associating proteasome
subunits, and possible mechanistic
connections with the classic polyubi-
quitylation mode of proteasome tar-
geting (Pickart and Cohen, 2004). Re-
gardless of the details, the emerging
roles for gankyrin in phosphorylation,
ubiquitylation, and degradation indi-
cate that it coordinates multiple critical
steps in enforcing the specificity and
efficiency of p53 and Rb regulation.
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